Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod (RPC1063) in moderate to severe ulcerative colitis
NCT02531126Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2015
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of ozanimod in ulcerative colitis (UC), sponsored by Celgene Corporation. Started Dec 2015; status: completed.
02
Drugs
ozanimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02531126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531126.